Use of molecular surveillance data to identify clusters of recent and rapid HIV transmission

Alexa Oster, MD
Acting Lead, Incidence and Molecular Epidemiology Team
Lead, Molecular HIV Surveillance
Division of HIV/AIDS Prevention
Centers for Disease Control and Prevention

March 24, 2017
Background
Identifying active HIV transmission is key to focusing prevention efforts

- Important to identify growing clusters of recent and rapid transmission in order to intervene to interrupt transmission

- How do we identify clusters of recent and rapid transmission?
  - HIV case surveillance data can identify trends in diagnoses, but, particularly in high burden areas, these data may obscure growing clusters of active transmission amid other trends
  - Partner services/contact tracing data provide information about transmission networks, however:
    - Not all index patients are interviewed
    - Many partners not named or located
    - Named partners may not represent transmission partners
    - Many jurisdictions do not offer partner services for all new diagnoses
HIV nucleotide sequence data are available and can identify active transmission

- In the United States, drug resistance testing is recommended for all HIV-infected persons
  - Generates HIV nucleotide sequence data

- Harnessing these nucleotide sequence data can provide information on transmission relationships and allows to
  - Construct transmission networks that link persons infected with genetically similar HIV variants
  - Identify growing clusters that represent active transmission
  - Focus prevention interventions
Monitoring and preventing HIV

- The National HIV Surveillance System (NHSS) is the primary source for monitoring HIV infection in the United States
  - Monitors and characterizes trends in HIV to guide public health action at the federal, state, and local levels
Molecular HIV surveillance (MHS): A component of the National HIV Surveillance System

- HIV nucleotide sequences
  - ATGGCATCAATGGCATCATTATCC
- Antiretroviral use information
- Demographics, risk, other case information
  - HIV Confidential Case Report Form

Purpose

- Assess prevalence of drug resistant strains
- Describe HIV transmission patterns
- Identification of clusters and potential outbreaks
- Monitor genetic diversity of HIV

Cluster Growth

Transmitted Drug Resistance among MSM by Number of Drug Classes and Year of Diagnosis
MHS jurisdictions (N=27), which reported 70% of new HIV diagnoses occurring in 2014.
Persons with HIV

Provider orders HIV drug resistance (genotypic) testing

Specimen sent to laboratory

Resistance report sent to provider

Laboratory performs genotypic testing (Sanger)

Specimen prepared

Viral RNA converted to DNA and amplified

Genetic sequence generated and compared with reference

Mutations identified and resistance interpreted

Resistance report sent to provider

HIV sequence reported electronically to health department

27 MHS jurisdictions
Using surveillance data to inform prevention
Ways to use molecular HIV data

- Monitor drug resistance (transmitted and acquired)
- Examine subtype diversity
- Understand transmission patterns
- Corroborate, refute, and understand suspected outbreaks (e.g., Indiana)
- Identify possible outbreaks and trigger investigation and intervention
- Monitor outbreaks over time
- Identify subgroups and networks with active transmission
- Prioritize prevention efforts
Molecular epidemiology and HIV

- HIV mutates/evolves over time
- People living with HIV infection whose viral strains are genetically similar may be more closely related in transmission

Analysis: compares nucleotide sequences to determine relatedness

- ACCGGATAACGGTTATCCG
- ACTGGATAACGGTTATCCG
- ACCGGATAACGGTTATCCG
- ACCGAATCAGGAAATCCG
Identifying transmission clusters

- Compare all pairs of sequences to calculate genetic distance between them
- Identify pairs of sequences that are very closely related
- Connect all closely related pairs to identify clusters

Link drawn between 2 sequences with close genetic distance

Image courtesy of Joel Wertheim
Molecular epidemiology and HIV

- Analysis: compares nucleotide sequences to determine relatedness

Person A infected person B
Person B infected person A
Person A infected person C, who infected person B
Persons D infected persons A and B

We can infer a direct OR indirect epidemiologic link; we cannot infer directionality
Hypothetical molecular cluster identified through sequence analysis

- HIV-infected, diagnosed, linked to care
- HIV-infected, diagnosed but not linked to care
- HIV-infected, not diagnosed
- HIV-uninfected, at risk
Interpreting transmission cluster data

- A transmission cluster includes only those cases that have been diagnosed and have a sequence.

- This represents a subset of the underlying transmission cluster and risk network, which can also include:
  - People who are diagnosed but do not have a sequence included in analysis
    - Diagnosed, but never linked to care
    - Linked to care, but haven’t received a genetic resistance test
    - Sequence hasn’t been reported to health department
  - People with undiagnosed infection
  - HIV-negative contacts who may be at risk of acquiring HIV
Hypothetical underlying sexual/risk network

- HIV-infected, diagnosed, linked to care
- HIV-infected, diagnosed but not linked to care
- HIV-infected, not diagnosed
- HIV-uninfected, at risk
Routine CDC analyses to identify active transmission clusters

- Each quarter, analyze data to identify growing clusters that represent recent, rapid transmission
  - Clusters are prioritized to identify the most concerning clusters nationally
  - Tightly related cases, suggesting rapid transmission
  - At least 5 cases in the cluster identified in most recent 12 month period

- Initial analysis of data collected through December 2015
  - 1,923 clusters identified, ranging in size from 2-22 cases
  - Of these, 13 met our criteria for rapid growth, with at least 5 cases in most recent 12-month period
### Characteristics of 13 high priority clusters

<table>
<thead>
<tr>
<th>Cluster ID</th>
<th>Total in cluster</th>
<th>Diagnosed in 2015</th>
<th>MSM</th>
<th>Drug resistance</th>
<th>Virally suppressed§</th>
<th>Primary census region*</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>16</td>
<td>8</td>
<td>94%</td>
<td>3 of 16</td>
<td>69%</td>
<td>Northeast</td>
</tr>
<tr>
<td>B</td>
<td>22</td>
<td>7</td>
<td>91%</td>
<td>17 of 17</td>
<td>68%</td>
<td>West</td>
</tr>
<tr>
<td>C</td>
<td>21</td>
<td>7</td>
<td>86%</td>
<td>20 of 20</td>
<td>57%</td>
<td>South</td>
</tr>
<tr>
<td>D</td>
<td>18</td>
<td>7</td>
<td>83%</td>
<td>0 of 17</td>
<td>67%</td>
<td>South</td>
</tr>
<tr>
<td>E</td>
<td>17</td>
<td>7</td>
<td>94%</td>
<td>15 of 15</td>
<td>94%</td>
<td>Northeast</td>
</tr>
<tr>
<td>F</td>
<td>15</td>
<td>7</td>
<td>93%</td>
<td>15 of 15</td>
<td>73%</td>
<td>South</td>
</tr>
<tr>
<td>G</td>
<td>16</td>
<td>6</td>
<td>100%</td>
<td>14 of 14</td>
<td>63%</td>
<td>West</td>
</tr>
<tr>
<td>H</td>
<td>6</td>
<td>6</td>
<td>100%</td>
<td>0 of 6</td>
<td>67%</td>
<td>West</td>
</tr>
<tr>
<td>I</td>
<td>18</td>
<td>5</td>
<td>94%</td>
<td>0 of 17</td>
<td>78%</td>
<td>South</td>
</tr>
<tr>
<td>J</td>
<td>17</td>
<td>5</td>
<td>94%</td>
<td>0 of 16</td>
<td>82%</td>
<td>Multiple, incl. Midwest</td>
</tr>
<tr>
<td>K</td>
<td>17</td>
<td>5</td>
<td>100%</td>
<td>0 of 16</td>
<td>77%</td>
<td>South</td>
</tr>
<tr>
<td>L</td>
<td>7</td>
<td>5</td>
<td>86%</td>
<td>0 of 6</td>
<td>43%</td>
<td>West</td>
</tr>
<tr>
<td>M</td>
<td>6</td>
<td>5</td>
<td>100%</td>
<td>0 of 6</td>
<td>17%</td>
<td>West</td>
</tr>
</tbody>
</table>

§Most recent viral load was suppressed and occurred in the past 12 months

*10 of 13 clusters included cases from more than one surveillance jurisdiction
What steps is CDC taking as we identify high priority clusters?

- Analyze national surveillance data for cluster and create cluster snapshot
- Discuss cluster findings with relevant state or local health departments
- Communicate and collaborate with health departments on
  - Investigation
  - Intervention
- Quarterly updates provide information on new cases added to previously identified clusters, as well as identifying new clusters meeting the priority criteria for the first time
  - Analysis of 5 quarterly data sets to date have identified approximately 60 total priority clusters
  - As of December 2016, sequences available for >250,000 cases nationally
Cluster investigation is critical

- Necessary to determine the underlying transmission cluster and risk network
  - Identify persons with diagnosed HIV infection that did not have a sequence included in analysis but are likely cluster cases, and could be contributing to ongoing transmission
  - Identify partners in the network that have not received a diagnosis of HIV infection for
    - Testing or retesting
    - Prevention efforts

- Determine characteristics of the cluster that could be contributing to ongoing transmission

- Understanding the cluster allows public health officials to implement public health interventions tailored to the characteristics of the cluster (i.e., geographic, risk, and clinical)
Intervene in entire network as appropriate

- HIV-infected, diagnosed, linked to care
- HIV-infected, diagnosed but not linked to care
- HIV-infected, not diagnosed
- HIV-uninfected, at risk
## Intervening in transmission clusters: Individual-level interventions

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Potential action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persons with diagnosed infection who are in care but unsuppressed</td>
<td>Promote viral suppression</td>
</tr>
<tr>
<td>Persons with diagnosed infection who are not in care</td>
<td>Promote engagement in care, viral suppression</td>
</tr>
<tr>
<td>Persons with undiagnosed infection</td>
<td>Identify (e.g., through partner services or social networks testing project) and link to care</td>
</tr>
<tr>
<td>HIV-negative persons at risk for acquiring HIV</td>
<td>Identify (e.g., through partner services or social networks testing project) and offer PrEP</td>
</tr>
</tbody>
</table>
## Intervening in transmission clusters: Cluster-level interventions

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Potential action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cluster associated with a particular venue</td>
<td>Targeted outreach for testing and PrEP</td>
</tr>
<tr>
<td>Cluster in a remote location</td>
<td>Educate providers on testing and treatment</td>
</tr>
<tr>
<td>Cluster spans multiple jurisdictions</td>
<td>Collaborate to intervene appropriately</td>
</tr>
<tr>
<td>Cluster associated with injection drug use</td>
<td>Ensure/expand appropriate provision of syringe exchange and substance use treatment</td>
</tr>
<tr>
<td>Cluster affects a specific population</td>
<td>Communicate with population at risk about transmission risk</td>
</tr>
</tbody>
</table>
An example cluster
One cluster example

- NHSS data from December 2015
  - 13 clusters met criteria for rapid growth: at least 5 cases in most recent 12 month period
- One cluster in TX was particularly concerning
  - As of December 2015 data: 18 members
  - As of June 2016 data: 24 members
  - Primarily young Hispanic/Latino MSM in one metropolitan statistical area
- CDC and TX Department of State Health Services partnered to investigate

- Methods: abstraction of medical records and partner services records
Key investigation findings

- Used partner services data to identify people who might have been part of the transmission cluster but didn’t have sequence data
  - Molecular cluster members: n=24
  - Other people who were sexual or needle sharing partners of molecular cluster cases and their partners: n=87

- Abstracted medical records to understand epidemiology of the cluster and identify factors that may have facilitated transmission
  - Despite high levels of risk behaviors and large numbers of partners (many of whom were anonymous partners), no patients had previously taken PrEP
  - Some patients had not been tested using the appropriate algorithm \(\rightarrow\) missed opportunity to diagnosed acute infection
Timing of exposure and infectiousness among molecular cluster members
Actions taken to address community factors

- Drafted a Dear Colleague letter
  - Outlines the rapid growth clusters observed
  - Recommendations for following HIV testing algorithm
  - Recommendations to prescribe PrEP to patients at risk
- Drafted a health alert
  - Will go out to entire state, medical providers and stakeholders
  - Details the need to use diagnostic algorithm to identify acute HIV cases
  - Recommends HIV genotype testing to identify these clusters
- 70% increase in prevention funding to San Antonio from DSHS
  - Will fund more testing and additional PrEP clinics
- Expanding options for notification of ‘anonymous’ partners via apps and social media sites
A cluster example
Ongoing efforts

- Guidance for detecting, investigating, and responding to transmission clusters released this month
- Continuing to expand collection of nucleotide sequence data
- Developing bioinformatics tools to automate analysis and visualization of molecular data at national and state/local levels
- Building our knowledge base on optimal approaches to investigate and respond to clusters
Summary

- Molecular analysis provides an opportunity to identify bursts of recent and rapid transmission
  - The current level of HIV transmission in the United States is likely largely sustained by these types of bursts of transmission

- Using molecular surveillance data to identify, investigate and intervene recent HIV transmission events can support efforts to improve health outcomes and prevent transmission among these networks
  - May allow us to make progress in reducing new infections in populations that have not yet seen reductions in incidence

- Cluster data can be a powerful tool to help target the interventions we know are effective (engagement in care, HIV testing, PrEP)
Acknowledgments

Local & state HIV surveillance staff

Division of HIV/AIDS Prevention

- Ells Campbell
- Sharoda Dasgupta
- Irene Hall
- Angela Hernandez
- Anne Marie France
- Cheryl Ocfemia
- Nivedha Panneer
- Neeraja Saduvala
- Bill Switzer

University of California, San Diego:
- Joel Wertheim

TX Department of State Health Services:
- Analise Monterosso